Toripalimab Combined With SBRT for NSCLC
This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for operable or potentially operable stage IIa to IIIb NSCLC
Non-small Lung Cancer
DRUG: Toripalimab|DRUG: Toripalimab
Major pathological remission rate, The percentage of residual live tumor cells in the tumor bed after neoadjuvant therapy is ≤ 10%, regardless of whether there are residual live tumor cells in the lymph nodes., 30 day
Complete pathological remission rate, After a complete evaluation of excised lung cancer specimens, including lymph nodes in all sampling areas, there was a lack of any surviving tumor cells when re examining HE slides, 30 day|disease-free survival（DFS）, The time interval between receiving surgical treatment and tumor recurrence or death due to tumor progression, 3 years|overall survival, The time interval between receiving surgical treatment and the patient's death due to any reason, and the patient is still alive during the final follow-up, with the survival time ending at the last follow-up., 3 years
Adverse events, Adverse events (AEs) related to the investigational drug, laboratory test outliers, and serious adverse events (SAEs) determined according to the NCI-CTCAE V5.0 standard, 24 hours
This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for operable or potentially operable stage IIa to IIIb NSCLC